Jubilant Pharmova Ltd has reported its Q2 FY25 results, showcasing robust growth across key financial metrics and expanding profitability in major business segments. The company saw an increase in both income and EBITDA margins, driven by its Radiopharma, CDMO Sterile Injectables, and Generics segments.
Key Financial Highlights:
- Total Income: ₹1,774 crore, a 5% YoY increase from ₹1,690 crore in Q2 FY24.
- EBITDA: ₹311 crore, up 19% YoY from ₹261 crore in Q2 FY24.
- EBITDA Margin: Expanded by 210 basis points, reaching 17.5% compared to 15.4% in Q2 FY24.
- Reported PAT: ₹103 crore, growing 65% YoY from ₹62 crore in Q2 FY24.
Segmental Performance:
1. Radiopharma
- Revenue: ₹251 crore
- EBITDA Margin: 48%
- This segment continues to maintain its strong market position, with growth driven by high-margin SPECT imaging products. The company is expanding its PET radiopharmacy network, set to include 52 sites across the US.
2. CDMO Sterile Injectables
- Revenue: ₹302 crore
- EBITDA growth: 59% YoY, reaching ₹89 crore.
- The segment benefited from increased capacity utilization and new product launches. The company is on track to start commercial production in FY26/FY27.
3. Generics
- Became profitable in Q2 FY25, contributing ₹173 crore in revenue.
- EBITDA margins remained stable at 12%, supported by strategic cost-cutting measures and scaling up of profitable products.
4. Allergy Immunotherapy
- Revenue: ₹170 crore
- EBITDA: ₹46 crore
- This segment saw a decline in YoY revenue due to lower demand from non-US markets, but the company expects revenue normalization in the second half of FY25.
